Summary
Merck & Co., Inc. reported strong financial results for the first quarter ended March 31, 2022, with total sales increasing by a significant 50% year-over-year to $15.9 billion. This growth was primarily driven by substantial sales of Lagevrio, its COVID-19 antiviral treatment, which generated $3.2 billion in revenue. Keytruda, the company's flagship oncology drug, also demonstrated robust performance with a 23% increase in sales, alongside strong contributions from its vaccine portfolio, notably Gardasil and Gardasil 9. Despite the overall positive financial performance, the company's gross margin saw a decline due to the lower margin profile of Lagevrio and increased manufacturing costs. The company also reported a substantial increase in Research and Development expenses, indicating continued investment in its pipeline. Looking ahead, Merck anticipates lower Lagevrio sales in subsequent quarters and faces upcoming patent expirations for key diabetes medications like Januvia and Janumet, which will likely impact future revenue streams. The company also continues to navigate ongoing legal proceedings and is closely monitoring the geopolitical situation in Ukraine.
Financial Highlights
51 data points| Revenue | $15.90B |
| Cost of Revenue | $5.38B |
| Gross Profit | $10.52B |
| R&D Expenses | $2.58B |
| SG&A Expenses | $2.32B |
| Operating Income | $4.31B |
| Interest Expense | $243.00M |
| Net Income | $4.31B |
| EPS (Basic) | $1.70 |
| EPS (Diluted) | $1.70 |
| Shares Outstanding (Basic) | 2.53B |
| Shares Outstanding (Diluted) | 2.54B |
Key Highlights
- 1Total sales surged 50% year-over-year to $15.9 billion, driven by strong performance across multiple therapeutic areas.
- 2Lagevrio, Merck's COVID-19 antiviral, was a major revenue contributor, generating $3.2 billion in sales.
- 3Keytruda, the oncology blockbuster, showed continued strength with a 23% increase in sales, supported by new indications and global uptake.
- 4The vaccine segment, particularly Gardasil and Gardasil 9, experienced significant growth, up 59%.
- 5Gross margin decreased to 66.2% from 69.9% in the prior year, primarily due to the inclusion of Lagevrio sales and higher manufacturing costs.
- 6Research and Development expenses increased by 7% to $2.58 billion, reflecting ongoing investment in the company's pipeline.
- 7Merck anticipates lower sales for Lagevrio in the remaining quarters of 2022, projecting full-year sales between $5.0 billion and $5.5 billion.